October 7, 2015October 7, 2015

IQWiG Dossier Assessment Shows No Added Benefit of Ceritinib (Zykadia) in NSCLC

Lung Cancer, News

A new report from one of Germany’s public health agencies is shedding new light on an approved therapy often used in the treatment of non-small cell lung cancer. Ceritinib (Zykadia) was approved ... Read more

March 11, 2015March 11, 2015

Zykadia by Novartis Recommended For EU Approval To Treat ALK+ NSCLC Patients Previously Treated With Crizotinib

Lung Cancer, News

Zykadia from Novartis was recommended for EU approval to address treatment for adult patients suffering from anapestic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), also known as ALK+NSCLC, which has been treated previously with crizotinib. If ... Read more